What oral medications are recommended for treating hyponatremia, including dosing and indications?

Oral Medications for Hyponatremia

For euvolemic hyponatremia (SIADH), tolvaptan 15 mg daily is the most effective oral medication, titrated to 30-60 mg based on sodium response, though oral urea (30-40 g divided 2-3 times daily) represents a safer, less expensive alternative with sustained efficacy. 1, 2, 3

Treatment Algorithm by Clinical Context

SIADH (Euvolemic Hyponatremia)

First-line approach:

• Fluid restriction to 1.0-1.5 L/day for sodium <120-125 mmol/L 1
• Adequate solute intake (salt and protein) 4
• Nearly 50% of SIADH patients fail fluid restriction, requiring escalation 4

Second-line oral medications when fluid restriction fails:

Tolvaptan (Vasopressin V2 Receptor Antagonist):

• Dosing: Start 15 mg once daily, titrate to 30 mg, then 60 mg if needed based on sodium response 1, 2
• Efficacy: Significantly improves sodium by day 4, maintained through 30 days of treatment 1
• Monitoring: Must initiate in hospital with frequent sodium checks to avoid overcorrection (>8-10 mmol/L per 24 hours) 2, 5
• Critical warnings:
  • FDA restricts use in liver cirrhosis due to hepatotoxicity risk (4.4% vs 1.0% ALT elevation >3x normal) 1
  • Avoid in patients unable to sense/respond to thirst (encephalopathy) due to dehydration/hypernatremia risk 2
  • Drug interactions: CYP3A inhibitors (ketoconazole, clarithromycin, grapefruit juice) cause dangerous sodium spikes 2
• Side effects: Thirst, dry mouth, polyuria; rare hypernatremia 1, 6

Urea:

• Dosing: 30-40 g orally divided 2-3 times daily (or 80 g as 30% solution over 6 hours for rapid correction) 5, 7
• Efficacy: Induces osmotic diuresis with sodium retention; corrects sodium from 117 to 134.5 mmol/L within 24 hours in acute symptomatic cases 7
• Advantages: Safe, inexpensive, sustained correction without relapse 3, 8
• Disadvantages: Poor palatability, gastric intolerance 3
• Monitoring: Effective in both SIADH and cerebral salt wasting when combined with sodium supplements and fluid restriction 5

Demeclocycline:

• Role: Last-line option due to nephrotoxicity risk 9, 8
• Mechanism: Induces nephrogenic diabetes insipidus
• Use only when: Vaptans and urea have failed or are contraindicated

Oral Sodium Chloride Tablets:

• Dosing: Hourly administration calculated to deliver equivalent of 0.5 mL/kg/h of 3% NaCl 10
• Role: Alternative to IV hypertonic saline in selected severe cases when ICU unavailable
• Requires: Hourly sodium monitoring, careful calculation to avoid overcorrection

Liver Cirrhosis with Hypervolemic Hyponatremia

Outpatient management (asymptomatic):

• Sodium AND water restriction (1-1.5 L/day fluid limit) 11
• Modify/reduce diuretics and laxatives 11
• Monitor electrolytes closely

Inpatient management (severe/symptomatic):

• Continue sodium and water restriction 11
• Discontinue or modify diuretics 11
• Add IV albumin based on volume assessment 11
• Consider oral vasoconstrictors (midodrine) 11

Vaptans in cirrhosis:

• Lixivaptan: 100-200 mg normalized sodium in 27-50% but caused severe dehydration/hypotension; discontinued in cirrhosis trials 1
• Satavaptan: 5-25 mg/day improved sodium (4.5-6.6 mmol/L increase) but increased mortality in reduced liver function (HR 1.47) with long-term use 1
• Tolvaptan: FDA restricts use; European approval requires monthly liver function tests 1
• Asian dosing: China/Japan approve 7.5-15 mg/day for ascites with hepatotoxicity warnings 1

Refractory cases require multidisciplinary approach including transplant team, considering:

• IV vasoconstrictors
• Hypertonic saline infusion
• Vaptans (with extreme caution)
• Renal replacement therapy 11

Heart Failure with Hypervolemic Hyponatremia

Tolvaptan:

• Approved for severe hypervolemic hyponatremia (<125 mmol/L) 2, 12
• Improves mental component quality of life scores 12
• Critical limitation: Long-term therapy did NOT improve mortality 12
• Recommendation strength: "May be considered" (Class IIb) for symptomatic hyponatremia 12

Neurosurgical Patients (SIADH)

Mild-moderate symptoms (nausea, headache, Na <120):

• Fluid restriction 1 L/day 5
• Oral NaCl 100 mEq three times daily if no response 5
• High protein diet 5

Asymptomatic:

• Fluid restriction 1 L/day 5
• Daily sodium monitoring 5

Subarachnoid hemorrhage patients:

• Never use fluid restriction (increases cerebral infarction risk: 21/26 fluid-restricted patients developed infarction vs 19/90 normonatremic) 5
• Fludrocortisone: 0.1 mg three times daily prevents negative sodium balance, reduces cerebral ischemia (22% vs 31%) 5
• Hydrocortisone: 1200 mg/day for 10 days prevents natriuresis, maintains CVP 5

Critical Safety Principles

Correction limits (all causes):

• Maximum: 8-10 mmol/L per 24 hours to prevent osmotic demyelination 2, 5, 13
• Acute symptomatic: Correct 6 mmol/L over 6 hours until severe symptoms resolve, then slow to stay within 24-hour limit 5
• Chronic hyponatremia: Gradual correction preferred; rapid correction risks osmotic demyelination (parkinsonism, quadriparesis, death) 5, 3

Common pitfalls:

• Overcorrection occurs in 4.5-28% with hypertonic saline 3
• Vaptans cause unpredictable correction rates—hospital monitoring mandatory 2, 6
• Drug interactions with CYP3A inhibitors dramatically increase vaptan effects 2
• Relapse common after vaptan discontinuation 8

When standard therapy fails:

• Reassess underlying diagnosis (exclude hypothyroidism, adrenal insufficiency, medication causes) 9, 6
• Verify true SIADH vs cerebral salt wasting (measure urine sodium, assess volume status) 5
• Consider urea as safest escalation option 8, 4
• Reserve vaptans for refractory cases with appropriate monitoring 8